65971-74-6

Basic information

• Product Name: Acetamide, N-(3-bromophenyl)-2-(hydroxyimino)-
• CAS NO: 65971-74-6
• Molecular Formula: C8H7BrN2O2
• Molecular Weight: 243.06
• Mol File: 65971-74-6.mol
• Article Data: 26

Chemical Properties

• CAS DataBase Reference: Acetamide, N-(3-bromophenyl)-2-(hydroxyimino)-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-(3-bromophenyl)-2-(hydroxyimino)-(65971-74-6)
• EPA Substance Registry System: Acetamide, N-(3-bromophenyl)-2-(hydroxyimino)-(65971-74-6)

Safety Data

• Hazardous Substances Data: 65971-74-6(Hazardous Substances Data)

Usage

General Description

Acetamide, N-(3-bromophenyl)-2-(hydroxyimino)-, also known as 3-Bromo-N'-hydroxyiminoacetanilide, is a chemical compound with the molecular formula C8H8BrN3O2. It is a hydroxyimino acetanilide derivative with a bromine atom attached to the phenyl group. This chemical is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active compounds and pharmaceuticals. Its structure and properties make it useful for the development of potential drug candidates and as a reagent in chemical reactions. Acetamide, N-(3-bromophenyl)-2-(hydroxyimino)- is also known for its potential antimicrobial and antifungal properties.

Upstream product

• 75-87-6 chloral 
• 591-19-5 m-Bromoaniline 
• 302-17-0 chloral hydrate 

Downstream Products

• 76561-16-5 7-bromo-1,2-dihydro-3,1-4H-benzoxazine-2,4-dione 
• 77603-45-3 5-bromo-2,4-dihydro-1H-3,1-benzoxazine-2,4-dione 
• 114703-12-7 7-bromoquinazoline-2,4(1H,3H)-dione 
• 20776-50-5 2-amino-4-bromobenzoic acid 
• 1374203-78-7 4-(3-{2-fluoro-4-[7-(5-methyl-furan-2-yl)4-morpholin-4-yl-quinazolin-2-yl]-phenyl}ureido)dimethyl-benzamide 
• 1374203-80-1 5-(2-(4-(3-(4-(dimethylcarbamoyl)phenyl)ureido)phenyl)-4-morpholino-quinazolin-7-yl)furan-2-carboxylic acid 
• 1374208-57-7 methyl 5-(2-(4-(3-(4-(dimethylcarbamoyl)phenyl)ureido)phenyl)-4-morpholino-quinazolin-7-yl)furan-2-carboxylate 
• 1374203-82-3 4-(3-(4-(7-(5-cyanofuran-2-yl)-4-morpholino-quinazolin-2-yl)-3-fluorophenyl)ureido)-N,N-dimethyl-benzamide 
• 1374203-83-4 4-(3-(4-(7-(5-acetylfuran-2-yl)-4-morpholino-quinazolin-2-yl)phenyl)ureido)-2-fluoro-N,N-dimethyl-benzamide 
• 1374203-87-8 N-(4-(3-(4-(7-(5-methylfuran-2-yl)-4-morpholino-quinazolin-2-yl)phenyl)ureido)phenyl)acetamide 
• 1374203-88-9 1-(4-(7-(5-methylfuran-2-yl)-4-morpholino-quinazolin-2-yl)phenyl)-3-(4-(2-oxopyrrolidin-1-yl)phenyl)urea 
• 1374203-71-0 N,N-dimethyl-4-(3-{4-[4-morpholin-4-yl-7-pyrimidin-5-yl-quinazolin-2-yl]-phenyl}-ureido)-benzamide 
• 959237-68-4 7-bromine-2,4-dichloroquinazoline 
• 1374203-73-2 4-(3-{5-[7-(3-methanesulfonyl-phenyl)-4-morpholin-4-yl-quinazolin-2-yl]-pyridin-2-yl}-ureido)-dimethyl-benzamide 

Relevant articles and documents

Saccharomonosporine A inspiration; synthesis of potent analogues as potential PIM kinase inhibitors

Saccharomonosporine A was recently reported as a natural anti-cancer agent working through inhibition of a Proviral integration site for Moloney murine leukemia virus-1 (PIM-1) kinase. Structural bioisosteres of this natural product were synthesized and t

Indolone compound as well as preparation method and application thereof

The invention relates to an indolone compound, which is 1-(4-chlorobenzyl)-3-(hydroxyimino)-4-(4-(trifluoromethyl)phenyl)-dihydroindol-2-one. The indolone compound can be used for effectively inhibiting the activity of an hTERT gene promoter; shown by a s

Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4

Transient Receptor Potential Vanilloid 4 (TRPV4) is a member of the Transient Receptor Potential (TRP) superfamily of cation channels. TRPV4 is expressed in the vascular endothelium in the lung and regulates the integrity of the alveolar septal barrier. Increased pulmonary vascular pressure evokes TRPV4-dependent pulmonary edema, and therefore, inhibition of TRPV4 represents a novel approach for the treatment of pulmonary edema associated with conditions such as congestive heart failure. Herein we report the discovery of an orally active, potent, and selective TRPV4 blocker, 3-(1,4′-bipiperidin-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide (GSK2193874, 28) after addressing an unexpected off-target cardiovascular liability observed from in vivo studies. GSK2193874 is a selective tool for elucidating TRPV4 biology both in vitro and in vivo.